The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway

The insulin-like growth factor-I receptor as an oncogene

(2011) Haim Werner et al.   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma

(2010) M. B. Wozniak et al.   HAEMATOLOGICA

Biomarkers for predicting clinical responses to HDAC inhibitors

(2009) Lindsay Stimson et al.   CANCER LETTERS

Vorinostat in solid and hematologic malignancies

(2009) David Siegel et al.   Journal of Hematology & Oncology

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

(2009) A Gualberto et al.   ONCOGENE

A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer

(2008) M. J. Gunter et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Loss of Tuberous Sclerosis Complex-2 Function and Activation of Mammalian Target of Rapamycin Signaling in Endometrial Carcinoma

(2008) K. H. Lu et al.   CLINICAL CANCER RESEARCH

The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer

(2008) Cesare Gridelli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY